The effects of spinach-derived thylakoid supplementation in combination with calorie restriction on anthropometric parameters and metabolic profiles in obese women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled clinical trial

Fatemeh Pourteymour Fard Tabrizi1, Mahdieh Abbasalizad Farhangi2*, Maryam Vaezi3,4 and Salar Hemmati5

Abstract

Background: There is a promising outlook regarding the potential effect of spinach-derived thylakoids in the management of obesity and its associated metabolic disturbances. This research aimed to evaluate the effects of spinach-derived thylakoids supplementation combined with a calorie-restricted diet on anthropometric and metabolic profiles in obese women with the polycystic ovary syndrome (PCOS).

Methods: In a 12-week double-blind placebo-controlled randomized clinical trial, 48 females with obesity and PCOS were randomly allocated into either intervention (5 g/day thylakoid) or placebo (5 g/day cornstarch) groups along with calorie-restricted diets. Anthropometric measures, physical activity levels, dietary intakes, insulin resistance markers, as well as serum levels of insulin, fasting blood glucose (FBG), non-esterified fatty acids (NEFA), and sex hormones including dehydroepiandrosterone sulfate (DHEAS), follicle-stimulating hormone (FSH), luteinizing hormone (LH), sex hormone-binding globulin (SHBG), and free androgen index (FAI) were evaluated pre-and post-intervention.

Results: After the 12-week intervention, there were significant decreases in weight (−6.97 ± 0.52 vs. -3.19 ± 0.72 kg; P < 0.001), waist circumference (−7.78 ± 2.50 vs. -3.73 ± 1.40 cm; P < 0.001), fat mass (−5.19 ± 0.53 vs. -1.36 ± 0.39 kg; P < 0.001), and insulin levels (−5.40 ± 1.86 vs. -1.19 ± 0.85 μU/mL; P < 0.001) in the spinach-derived thylakoid group compared to the placebo group. Furthermore, insulin resistance markers and serum levels of testosterone decreased significantly in the thylakoid group compared to the placebo group (P < 0.05). The changes in other parameters did not show significant differences between the two groups.

(Continued on next page)
Background

Polycystic ovary syndrome (PCOS), as the most common endocrine disorder in reproductive-aged women, is a multisystem disorder and a heterogeneous condition with a wide range of signs and symptoms [1]. It affects 5–20% of premenopausal women, depending on the population screened and the diagnostic criteria [2]. Based on the Rotterdam criteria, it was estimated that about 19.5% of Iranian women were affected with PCOS [3]. Mainly, the PCOS status influences reproductive, metabolic, social, and psychological facets of affected women’s lives [4]. Women with PCOS are characterized by irregular menstrual cycles, androgen excess symptoms (i.e., androgenic alopecia, hirsutism, and acne), obesity, and insulin resistance (IR) [5]. Hyperandrogenism and IR are chiefly involved in the pathogenesis of PCOS [6]. IR and concomitant compensatory hyperinsulinemia, are prevalent in PCOS; it is estimated that 50 to 75% of women with PCOS have hyperinsulinemia [7]. Obesity and overweight prevalence in PCOS was reported to be 61% in a meta-analysis conducted in 2012 [8]. There are complicated and interrelated interactions between IR, hyperandrogenism, changed ratio of the release of luteinizing hormone (LH) to follicle-stimulating hormone (FSH), and obesity; these interactions impair metabolic and hormonal profiles in obese women PCOS [5]. IR exacerbates hyperandrogenism through increased ovarian androgen production and decreased sex hormone-binding globulin (SHBG) production. On the other hand, increased production of androgens leads to IR and hyperinsulinemia [6, 9]; also, obesity can further exacerbate IR, hyperandrogenism, and menstrual irregularities [8]. There is no particular remedy or cure for PCOS, and therapeutics for PCOS management have typically focused on targeting the presentation of symptoms [10]. The first published international evidence-based guidelines for PCOS management, in 2018, emphasized the importance of inter-disciplinary care for women with PCOS and highlighted a healthy lifestyle, including a focus on a diet to attain and/or maintain a healthy weight to improve hormonal health and quality of life in women with PCOS [10]. Several studies have reported that a 5 to 10% weight loss can ameliorate clinical outcomes including, risk factors for cardiovascular disease, type 2 diabetes, and endocrine and reproductive parameters in PCOS sufferers [11]. Calorie-restricted diets are the first line of obesity management [12]. It has been reported that calorie-restricted diets (350–1000 kcal/day deficit) have considerable beneficial effects on the loss of body weight and fat mass, as well as amelioration of insulin sensitivity and menstrual cycle; hence, should be recommended as the first-line therapy in PCOS women [13, 14]. Further, there has been increasing interest in the use of phyto-nutraceuticals as complementary therapies to prevent and manage PCOS related complications [15]. Recent studies have shown that thylakoids, as chloroplast membranes in green leafy vegetables, extracted from spinach have anti-obesity effects [16, 17]. The beneficial effects of thylakoid intake on obesity and its related metabolic disturbances including, reduction of blood lipids and glucose and improvement of insulin resistance, are supported by some evidence [18, 19]. Considerable reduction in ratings of hunger and desire for high-sugar foods as well as salty and high-fat foods is the most common effect that has been demonstrated by studies [16–18]. In a clinical trial, the supplementation of obese women with 5 g/day thylakoid (as a glass of blueberry juice containing 5 g thylakoid) for 3 months, resulted in significant decreases in body weight, waist circumference, low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), and fasting insulin [18]. To the best of our knowledge, there is no study investigating the effects of spinach-derived thylakoid supplementation with or without a calorie-restricted diet on the hormonal parameters and metabolic status in obese women with PCOS. Therefore, the evaluation of the effects of thylakoid consumption in combination with a calorie-restricted diet on anthropometric parameters and metabolic profiles in obese women with PCOS was the purpose of the present study.

Methods

Study design and participants

This study was a randomized, double-blind, placebo-controlled clinical trial, conducted from September 2018 through May 2019, in Tabriz, Iran. This clinical trial was registered in the Iranian Registry of Clinical Trials (http://www.irct.ir; registration no. IRCT20140907019082N9). The target population of the present study was obese women...
with PCOS who were recruited from Sheykholrasay Poly-
clinic and the gynecology and infertility clinics of Alzahra
Hospital in Tabriz, Iran. All patients were taking oral
contraceptive pills (OCPs) as a routine medical therapy
under the supervision of their physician. Forty-eight obese
women (body mass index (BMI): 30–40 kg/m²) aged 20–
45 years were enrolled. They were diagnosed with PCOS
based on Rotterdam criteria [20]. Two of the following
three features have to be present for the PCOS diagnosis:
(i) oligomenorrhea with eight or fewer menstruations in
the previous 12 months or amenorrhea, (ii) clinical and/or
biochemical signs of hyperandrogenism, and (iii) polycystic
ovaries on ultrasound examination (> 12 follicles, 2 to 9
mm in diameter and/or increased ovarian volume > 10 mL).
The diagnosis of PCOS also required that there was no
evidence of thyroid disease, adrenocortical dysfunction, or
hyperprolactinemia (prolactin > 30 mg/mL). The main
exclusion criteria for participation in this study were: men-
opause, or pregnancy, or lactation; smoking or being exposed
to cigarette smoke (passive smoking); having co-morbidity
with other gynecologic or endocrine disease, or hepatic,
renal, or cardiovascular disease, diabetes and/or impaired
glucose tolerance; taking any nutritional or herbal supple-
ments during two months prior to the study, using ovula-
tion induction agents or drugs affecting metabolic or
insulin status such as statins, thiazolidinediones, corticoste-
roids, insulin, anti-obesity and anti-diabetic drugs (i.e.,
Metformin, sulfonylureas, etc.). If the patients had adopted a
diet and/or a specific physical activity program, or any
changes in medications, or experienced any detrimental
events during the study, they were withdrawn from the
clinical trial.

Ethics approval and consent to participate
The study was conducted according to the Declara-
tion of Helsinki guideline and approved by the ethics
committee of research vice-chancellor of Tabriz Uni-
versity of Medical Sciences, Tabriz, Iran (Ethics code:
IR.TBZMED.REC.1397.447); After being given a full
explanation of the study procedures, written informed
consent was obtained from all patients.

Sample size
The sample size for the study was calculated based on the
results mean (standard deviation; SD) for FBG as reported
by Stenblom et al. [21], with a confidence interval (CI) of
95%, and power of 90% in two-sided tests using power
analysis and sample size software (PASS; NCSS, LLC, US)
version 15, the sample size was 21 per group, which was
increased to 24, considering a probable 15% dropout rate.

Study protocol
The study participants were randomly allocated into one
of the two experimental groups (1:1), by the use of the
Random allocation software (RAS) and randomized
block procedure of size 2 (age (< 33 vs. ≥33) and BMI (<
35 kg/m² vs. ≥35 kg/m²)). Randomization and allocation
were concealed to the researchers and participants until
the final analyses were completed. The eligible subjects
were assigned to receive 5 g/day of thylakoid-rich spin-
ach extract or matching placebo as 5 g/day of raw corn
starch (one sachet, 30 min before lunch) for 12 weeks.
The sachets were completely identical in all other
aspects. The primary outcomes were changes in
anthropometric measurements and metabolic status. At
first, demographic and clinical questionnaires were com-
pleted for all participants. They were asked to complete
a 3-day food record questionnaire including, two week-
days and one weekend day in the week just prior to the
study and during weeks 6 and 12. The International
Physical Activity Questionnaire - short form (IPAQ-SF)
was also used to assess the physical activity level, at
baseline, week 6, and week 12. Next, anthropometric
measurements, bioelectric impedance analysis (BIA), and
blood pressure measurements were performed. After 12-
h overnight fasting, blood was taken from each patient
for biochemical evaluations before and after the interven-
tion. The participants were asked to keep their regular
medication (i.e., OCP) and usual levels of physical activity
throughout the study period. They were also advised to in-
form the researchers of any changes in their medical ther-
apy program and any adverse effects of the supplements.

Intervention protocol
Participants were randomly recruited to a 12-week inter-
vention arm consisting of 5 g/day of thylakoid-rich spin-
ach extract powder + low-calorie diet (n = 24) or to a
control arm of 5 g/day powdered raw cornstarch as pla-
cebo + low-calorie diet (n = 24). The choice of 12-week
intervention duration and a dose of 5 g/ day thylakoid
was based on previously reported beneficial effects of
thylakoid supplementation on obesity status and related
metabolic profiles in participants who received thylakoid
supplements for 12 weeks [16, 18]. All the participants
received a calorie-restricted diet designed by a dietitian.
For planning the calorie-restricted diet, total energy
expenditure was calculated based on resting energy
expenditure (REE), which was calculated based on the
Mifflin equation [22], physical activity level, and thermic
effect of food (10% of total energy expenditure). After
calculating the daily required energy for each particip-
ant, a calorie deficit of 500 kcal per day was made for each
person. Macronutrient distribution was organized as 30,
15, and 55% of energy from fat, protein, and carbohy-
drates, respectively. This distribution of macronutrients,
as moderate and conventional ratios instead of higher or
lower ratios (such as low fat or low carbohydrate or high
protein), was planned based on existing clinical nutrition
guidelines and aimed to increase adherence to the prescribed diet [23]. The participants were asked to pursue healthy eating recommendations, including substituting solid fats and animal fats with non-hydrogenated vegetable oils as well as limiting added sugar, desserts, sugar-sweetened beverages, saturated and trans fats, and fast foods as well as changing cooking methods to healthier ways. The application of food exchange lists was thoroughly explained to the participants, and they were advised of the alternative options with equal calories when a particular item from the corresponding food group is not affordable or available. Adherence to the recommended diet was evaluated using dietary intake records for 3 days (2 weekdays and 1 weekend) at the beginning, middle, and end of the study. Daily intakes of macro- and micro-nutrients were calculated by analyzing food data using nutritionist IV software (First Databank, San Bruno, CA).

Preparation of spinach thylakoids and placebo
Fresh baby spinach leaves (Spinacia oleracea) were used to prepare of thylakoid membranes according to the previously registered protocols [17, 24, 25]. The required spinach was collected from Tabriz, East Azerbaijan Province, Iran in spring, 2018; some plant samples were delivered to the Herbarium Center of the Faculty of Pharmacy, Tabriz University of Medical Sciences. The scientific name of the collected specimen is Spinacia oleracea L. belonging to the Oleracea family with the herbarium number TBZ-fph-1898. The thylakoid supplement used in this investigation was prepared based on the method described by Emerk et al. [25], at an experimental scale in the Synthesis Laboratory of Drug Applied Research Center, Tabriz University of Medical Sciences. Fresh spinach leaves after removing the stems and veins, were soaked in cold water and washed. Spinach leaves (1000 g) were homogenized with 1250 ml water in a blender and filtered through four layers of Monodur polyester mesh (20 μm). This obtained filtrate was diluted 10 times with distilled water, and its pH adjusted to 4.7 with Hydrochloric acid (HCl). PH 4.7 is the isoelectric point of the thylakoids, and maximum precipitation occurs at this pH. The thylakoids flocculated, and a green precipitate with a clear, a bit yellowish supernatant was obtained after 4 h standing in the cold (−4 °C). The supernatant was removed, and the green precipitate was collected from the filtrate thylakoids at pH 4.7 and washed in water by repeated centrifugation; the precipitation was repeated at the same pH. The washed thylakoids were collected, and after adjusting to the desired pH (pH 7.0), the final sediments freeze-dried to obtain a green thylakoid powder. Large scale production, of this freeze-dried thylakoid powder, was conducted by the Iran Darook Pharmaceutical Co., Tehran, Iran. Placebo consisted of corn starch, which was colored in edible green color, and like thylakoid powder, flavored with kiwifruit essence. Corn starch, a white, tasteless, safe, non-toxic, non-irritant, and non-allergenic odorless powder, is the most frequently used substance in the food and pharmaceutical industries, as an inert (inactive) substance without any therapeutic effect. Due to its versatility and flexibility in application, and ease of modification, we modified it to green powder with Kiwi odor, exactly like that extracted thylakoid from spinach. Therefore, green powder of thylakoid or placebo was made, with kiwifruit flavor and identical appearances (shape, size, and color). Next, they were packed in identical sachets with each sachet containing 5 g of thylakoid or 5 g of cornstarch powder. The contents of the sachets were dissolved in a glass of water and consumed 30 min before lunch. Packages were coded and distributed monthly by a third person who was not involved in any other aspects of the study. To remind participants to consume their supplements, a supplement consumption chart was provided. This chart was required to be returned at each visit to ensure compliance. Participants received a daily text message reminder and weekly a phone call reminds them to take the supplement. This helped to minimize study withdrawal and ensure adherence to the study protocol. The participants were asked to return the remaining sachets at each visit; counting these sachets allowed us to evaluate compliance. Consuming ≥80% of the supplements was considered compliant.

Anthropometric and body composition measurements
The height, weight, waist and hip circumferences, and body composition of the participants were measured at baseline, mid, and end of the study. BMI was calculated as weight (kg) divided by height in meters squared (m²). Body composition was assessed using Tanita MC-780 SMA (Amsterdam, the Netherlands). Tanita MC-780 MA is a body composition analyzer based on bioelectrical impedance analysis, which uses BIA technology, as quick, non-invasive, and one of the most thorough and reliable ways, to measure body composition [26].

Blood sampling and biochemical measurements
At pre- and post-intervention, a 10 ml venous blood sample was drawn from each participant. Blood sampling was done between 8:00 a.m. and 9:00 a.m. after a 12-h overnight fasting and resting in bed during the early follicular phase (d 2–5) of a spontaneous or P-induced menstrual cycle. Blood samples immediately centrifuged at 3500 rpm for 10 min, and serum samples were separated from whole blood and were frozen immediately at −80 °C until assay time. Measurements of serum non-esterified fatty acids (NEFA), FBG, and insulin were done on the sampling day. Serum FBG and
NEFA were measured through enzymatic methods using the colorimetric technique, by commercial kits (Pars-Azmoon Co., Tehran, Iran; and Biovision Research Product, USA, respectively) by an auto-analyzer (Hitachi-917, Tokyo, Japan). Serum insulin level was measured by chemiluminescence (IMMULITE 2000, SIEMENS); and the homeostatic model of assessment for insulin resistance (HOMA-IR) and β cell function (HOMA-B) and quantitative insulin sensitivity check index (QUICKI) were calculated on the basis of suggested formulas [27]. Hormonal profiles including LH, FSH, dehydroepiandrosterone sulfate (DHEAS), testosterone, and SHBG, were determined using ELISA kits (Bioassay Technology Laboratory, Shanghai Korean Biotech, Shanghai City, China) according to the manufacturer’s instructions with inter- and intra-assay coefficient variances (CVs) lower than 7%. The free androgen index (FAI) was calculated based on suggested formulas [28].

Statistical analysis
All statistical analyses were performed using SPSS version 23 (SPSS Inc., Chicago, IL, USA). The Kolmogorov-Smirnov test was performed to determine the normality of data distribution. Distribution of data was expressed as mean (SD) for normally distributed quantitative data, and frequency (percent) for qualitative data. To compare the two groups at the baseline, independent sample t-tests, Mann-Whitney, and chi-squared tests were used. Assessments of differences within the group were made by paired-samples t-tests or nonparametric Wilcoxon signed-rank test, and sign test. A comparison of the two groups at the end of the study was completed by the analysis of covariance (ANCOVA) after adjusting for the baseline parameters and covariates (changes in baseline values of evaluated parameters and potential covariates including age, baseline BMI, and the changes in weight, calorie intake, and physical activity level during the study). Post hoc paired comparisons were made by using a Sidak test. Results with $P$ values of < 0.05 were considered statistically significant.

Results
Baseline characteristics of participants
Forty-eight obese women with PCOS were recruited in the present clinical trial and randomized to receive either thylakoid or placebo; out of them, forty-four participants [thylakoid ($n = 21$) and placebo ($n = 23$)] completed the trial, while 4 participants discontinued the study for reasons irrelevant to the interventions (Fig. 1). During the trial, no adverse events or symptoms were reported following the intake of thylakoid powder by the participants. Sachet counts showed good compliance, with more than 90% of sachets taken during the course of the trial by both groups. No significant differences were seen in baseline parameters between the two groups (Table 1; $P > 0.05$). None of the participants were smokers. Physical activity levels of the participants did not change significantly throughout the study within or between the two groups ($P > 0.05$).

Dietary intakes and anthropometric measurements
As shown in Table 2, the baseline calorie and macronutrient intakes were not significantly different in the two groups ($P > 0.05$), except for saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) intakes, which were higher in the thylakoid group than the placebo group ($P < 0.05$). Both groups received a calorie-restricted diet; therefore, energy intake decreased in the two study groups compared to the baseline. At the end of the study, there were significant decreases in the intake of calories, carbohydrates, total fat, polyunsaturated fatty acids (PUFA), SFA, and MUFA in both thylakoid and placebo groups ($P < 0.05$). Intakes of protein, fiber, and cholesterol did not significantly change in both groups ($P > 0.05$). The between-group analyses adjusted for baseline measures and confounding factors showed no significant differences for these dietary intake parameters (Table 2). Regarding macronutrient distribution (as a percentage of total calorie intake), there were significant decreases in the percentage of calorie from carbohydrates (55% vs. 56.8% in the thylakoid group; 55% vs. 57% in the placebo group; $p < 0.001$ for both groups) and fats (30.2% vs. 32.4% in the thylakoid group; 30.1% vs. 32.2% in the placebo group; $p < 0.001$ for both groups). However, the percentage of total calorie from protein was significantly increased by the end of the study (15% vs. 10.8% in the thylakoid group; 15% vs. 10.7% in the placebo group; $p < 0.001$ for both groups). There was no significant difference between the two groups in terms of the changes in macronutrients distribution throughout the study.

As presented in Table 2, at the start of the study, no significant differences were seen in the baseline anthropometric indices including, weight, BMI, waist circumferences (WC), fat mass (FM), and fat-free mass (FFM), except in waist to hip ratio (WHR), between the two groups. After 12 weeks of intervention, changes in weight, BMI, WC, WHR, FM, and FFM were found to be significant and decreased in both study groups ($P < 0.05$). Based on the between-group analysis adjusted for baseline values and changes in dietary intakes and physical activity levels, thylakoid intake combined with a calorie-restricted diet led to significant decreases in weight, BMI, WC, WHR, and FM with no significant changes in FFM, compared to the placebo group (Table 2). Percent changes (PCs) for the anthropometric variables are presented in Fig. 2.

Glycemic indices and hormonal parameters
Table 3 presents the glycemic indices and hormonal parameters of subjects at baseline and after the intervention.
Table 1 Baseline characteristics of the study participants

| Variable               | Thylakoid group ($n = 21$) | Placebo group ($n = 23$) | $P$  |
|------------------------|-----------------------------|--------------------------|------|
| Age (y)$^d$            | 31.86 (2.35)                | 32.04 (2.83)             | 0.81$^a$ |
| Age at menarche (y) $^d$ | 12.40 (0.46)                | 12.33 (0.45)             | 0.59$^b$ |
| Height (cm) $^d$       | 159.33 (3.5)                | 158.00 (3.4)             | 0.21$^a$ |
| Physical activity $^e$ |                             |                          |      |
| Low                    | 19 (90.5)                   | 20 (87.0)                |      |
| Moderate               | 2 (9.5)                     | 3 (13.0)                 |      |
| High                   | 0 (0.0)                     | 0 (0.0)                  |      |

$^d$ Values are presented as mean (SD)
$^e$ Values are presented as number (%) 
$^a$ $P$ based on Independent-samples t-test
$^b$ $P$ based on Mann-Whitney U test
$^c$ $P$ based on chi square test
Table 2: Anthropometric measurements and dietary intakes of the study participants at the baseline and after 12 weeks of intervention

|                        | Thylakoid group (n = 21) | Placebo group (n = 23) | MD (95% CI), P     |
|------------------------|--------------------------|------------------------|--------------------|
| **Weight (kg)**        |                          |                        |                    |
| Baseline               | 89.21 (6.50)             | 88.14 (7.27)           | 1.06 (–3.14, 5.27), 0.612** |
| End                    | 82.23 (6.16)             | 84.95 (6.87)           | –3.71 (–4.03, –3.39), < 0.001*** |
| **BMI (kg/m²)**        |                          |                        |                    |
| Baseline               | 35.13 (2.16)             | 35.31 (2.77)           | –0.18 (–1.71, 1.34), 0.808** |
| End                    | 32.38 (2.08)             | 34.03 (2.60)           | –1.47 (–1.59, –1.35), < 0.001*** |
| **Carbohydrates (g)** |                          |                        |                    |
| Baseline               | 108.09 (3.89)            | 108.18 (4.22)          | –0.08 (–2.56, 2.39), 0.944** |
| End                    | 100.31 (4.58)            | 104.66 (3.75)          | –4.00 (–5.25, –2.76), < 0.001*** |
| **Cholesterol (mg)**   |                          |                        |                    |
| Baseline               | 202.70 (39.18)           | 198.20 (44.45)         | 54.13 (3.53)        |
| End                    | 200.39 (27.74)           | 190.62 (37.42)         | 19.68 (3.53)        |
| **Fat (g)**            |                          |                        |                    |
| Baseline               | 84.28 (13.73)            | 82.30 (16.00)          | 1.98 (–7.12, 11.09), 0.662** |
| End                    | 58.31 (3.92)             | 57.04 (3.99)           | 0.78 (–0.75, 2.32), 0.308*** |
| **PUFA (g)**           |                          |                        |                    |
| Baseline               | 20.15 (3.29)             | 17.20 (3.33)           | 2.95 (0.93, 4.97), 0.005** |
| End                    | 13.93 (0.86)             | 11.91 (0.78)           | –0.26 (–0.61, 0.09), 0.143*** |
| **MUFA (g)**           |                          |                        |                    |
| Baseline               | 41.85 (6.99)             | 42.81 (8.42)           | –0.96 (–5.70, 3.77), 0.685** |
| End                    | 28.96 (2.15)             | 29.68 (2.27)           | –0.27 (–1.06, 0.52), 0.491*** |
There were no significant differences in levels of FBG, insulin, NEFA, HOMA-IR, HOMA-β, QUICKI, and hormonal parameters between the two groups at baseline (P > 0.05). After 12 weeks of intervention, the serum concentrations of FBG and FSH did not change statistically in the two groups compared to baseline values (for both variables P > 0.05). In addition, at the end of the study, these parameters were not statistically different between the groups (P > 0.05). Changes in the HOMA-IR, HOMA-B, QUICKI, and fasting serum levels of insulin, NEFA, LH, total testosterone, and FAI were significant in both thylakoid and placebo groups compared to baseline values (all P < 0.05). At the end of the study, the levels of DHEA-S decreased, and SHBG increased significantly in the thylakoid group compared to baseline values (all P < 0.05). As shown in Table 3, results of the analysis of covariance after adjusting for the baseline values and potential confounding factors (changes in weight, physical activity, and calorie intake) revealed no significant between-group differences by the end of the study for these parameters, except for levels of insulin, total testosterone, HOMA-IR, HOMA-B, and QUICKI. Comparison between two groups indicated that the QUICKI levels increased, and levels of insulin, total testosterone, HOMA-IR, and HOMA-B decreased significantly in the thylakoid group compared to the placebo group (all P < 0.05). Accordingly, the between-group analysis showed that these parameter levels were improved significantly in the thylakoid treated group (P < 0.05).

**Discussion**

The findings of previous animal studies and clinical trials support the appetite-suppressing and weight-reducing properties of a thylakoid-rich spinach extract. These studies reported that thylakoid-rich spinach extract might help in the management of obesity and its related metabolic issues such as glycemia and insulin imbalances [17, 19, 29]. Due to the lack of similar studies on obese women with PCOS, the present double-blind placebo-controlled RCT was designed to assess the effects of caloric restriction in combination with thylakoid-rich spinach extract supplementation on the anthropometric measures, metabolic, and hormonal status in obese women suffering from PCOS. The current study, as the first clinical trial in this regard, showed that administration of 5 g/day of thylakoid-rich spinach extract in

---

**Table 2** Anthropometric measurements and dietary intakes of the study participants at the baseline and after 12 weeks of intervention (Continued)

|                     | Thylakoid group (n = 21) | Placebo group (n = 23) | MD (95% CI), P*  |
|---------------------|--------------------------|------------------------|-----------------|
| SFA (g)             |                          |                        |                 |
| Baseline            | 15.83 (2.69)             | 14.02 (2.74)           | 1.81 (0.15, 3.47), 0.033** |
| End                 | 11.04 (1.26)             | 9.72 (0.72)            | 0.04 (~0.12, 0.20), 0.585*** |
| MD (95% CI), P*     | -4.78 (~6.00, -3.57), 0.001 | -4.30 (~5.56, -3.04), 0.001 |       |
| Fiber (g)           |                          |                        |                 |
| Baseline            | 19.16 (5.52)             | 20.96 (3.88)           | -1.81 (~4.69, 1.08), 0.213** |
| End                 | 21.13 (5.38)             | 22.59 (4.54)           | -0.98 (~4.16, 2.20), 0.535*** |
| MD (95% CI), P*     | 1.97 (~1.23, 5.16), 0.213 | 1.62 (~0.52, 3.76), 0.130 |       |

Abbreviation: BMI body mass index, WC Waist circumference, WHR waist-to-hip ratio, FM fat mass, FFM fat free mass, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA polyunsaturated fatty acid; % Kcal, percentage of energy. Data are expressed as mean (standard deviation) and mean difference (95% CI). P*: Denotes the significance of within-group changes (Paired samples t-test). P**: P values indicate comparison between groups at baseline (Independent sample t-test for baseline). P***: P values indicate comparison between groups based on ANCOVA adjusted for baseline measures and confounding factors (age, baseline BMI, and the changes in weight, calorie intake, and physical activity level during the study).

---

**Fig. 2** Percent changes in anthropometric measures in thylakoid and placebo groups after 12 weeks’ intervention. P values obtained from intra group-paired analyses: the paired t-test. BMI: Body mass index, WC: Waist circumference, WHR: Waist-to-hip ratio, FM: Fat mass, FFM: Fat free mass.
Table 3 Comparison of metabolic and hormonal parameters between the thylakoid group and the placebo group at baseline and after the intervention

| Parameter                | Thylakoid group (n = 21)     | Placebo group (n = 23)     | MD (95% CI), P     |
|--------------------------|------------------------------|----------------------------|--------------------|
| FBG (mg/dl)              | Baseline 93.09 (5.39)        | 96.56 (7.44)               | −3.47 (−7.46, 0.52), 0.086** |
|                          | End 92.66 (4.70)             | 96.09 (6.10)               | −0.82 (−3.35, 2.79), 0.854*** |
|                          | MD (95% CI), P*              | −0.43 (−1.05, 0.19), 0.165 | −0.48 (−1.36, 0.40), 0.273 |
| Insulin (µU/mL)          | Baseline 17.97 (2.45)        | 18.63 (2.33)               | −0.66 (−2.11, 0.80), 0.370** |
|                          | End 12.57 (2.11)             | 17.43 (2.25)               | −3.73 (−7.06, 0.40), **0.029*** |
|                          | MD (95% CI), P*              | −5.40 (−6.25, −4.55), < 0.001 | −1.19 (−1.56, −0.83), < 0.001 |
| HOMA-IR                  | Baseline 4.14 (0.69)         | 4.43 (0.60)                | −0.29 (−0.68, 0.10), 0.143** |
|                          | End 2.87 (0.49)              | 4.13 (0.53)                | −1.26 (−1.88, 0.25), **0.011*** |
|                          | MD (95% CI), P*              | −1.27 (−1.48, −1.05), < 0.001 | −0.31 (−0.42, −0.19), < 0.001 |
| HOMA-B                   | Baseline 219.68 (40.36)      | 210.36 (55.60)             | 9.32 (−20.48, 39.13), 0.531** |
|                          | End 156.06 (37.50)           | 197.36 (49.16)             | −40.82 (−78.48, −3.16), **0.034*** |
|                          | MD (95% CI), P*              | −63.62 (−73.88, −53.37), < 0.001 | −13.00 (−17.53, −8.46), < 0.001 |
| QUICKI                   | Baseline 0.31 (0.007)        | 0.31 (0.006)               | 0.003 (−0.002, 0.007), 0.121** |
|                          | End 0.33 (0.008)             | 0.31 (0.005)               | 0.012 (0.002, 0.022), **0.022*** |
|                          | MD (95% CI), P*              | 0.02 (0.014, 0.02), < 0.001 | 0.003(0.002, 0.004), < 0.001 |
| NEFA (mmol/L)            | Baseline 0.89 (0.06)         | 0.93 (0.07)                | −0.03 (−0.07, 0.005), 0.084*** |
|                          | End 0.86 (0.06)              | 0.90 (0.06)                | 0.008 (−0.033, 0.048), 0.707*** |
|                          | MD (95% CI), P*              | −0.03 (−0.03, −0.02), < 0.001 | −0.02 (−0.03, −0.01), < 0.001 |
| LH (mlu/ml)              | Baseline 7.99 (0.42)         | 7.78 (0.38)                | 0.21 (−0.03, 0.45), 0.089** |
|                          | End 7.95 (0.42)              | 7.74 (0.36)                | −0.13 (−0.315, 0.059), 0.173*** |
|                          | MD (95% CI), P*              | −0.04 (−0.07, −0.006), 0.022 | −0.04 (−0.08, −0.006), 0.025 |
| FSH (mlu/ml)             | Baseline 4.49 (0.05)         | 4.53 (0.48)                | −0.05 (−0.35, 0.25), 0.751** |
|                          | End 4.47 (0.05)              | 4.52 (0.47)                | 0.024 (−0.08, 0.13), 0.652*** |
|                          | MD (95% CI), P*              | −0.01 (−0.03, 0.004), 0.124 | −0.01 (−0.03, 0.005), 0.146 |
| DHEA-S (µg/dl)           | Baseline 246.09 (9.58)       | 242.56 (7.42)              | 3.53 (−1.66, 8.72), 0.177** |
|                          | End 241.66 (5.65)            | 241.91 (5.88)              | 2.87 (−10.72, 16.47), 0.671*** |
|                          | MD (95% CI), P*              | −4.43 (−8.64, −2.22), **0.040 | −0.65 (−4.52, 3.21), 0.730 |
| Total testosterone (ng/ml)| Baseline 0.65 (0.06)         | 0.69 (0.08)                | −0.03 (−0.08, 0.01), 0.121** |
|                          | End 0.59 (0.03)              | 0.66 (0.07)                | −0.06 (−0.12, −0.004), **0.036*** |
|                          | MD (95% CI), P*              | −0.06 (−0.08, −0.004), < 0.001 | −0.03 (−0.03, −0.02), < 0.001 |
| SHBG (nmol/L)            | Baseline 25.83 (1.12)        | 25.76 (1.02)               | 0.07 (−0.58, 0.72), 0.824** |
|                          | End 26.28 (1.13)             | 25.97 (0.79)               | −0.52 (−2.02, 0.97), 0.483*** |
|                          | MD (95% CI), P*              | 0.45 (0.06, 0.84), **0.026 | 0.22 (−0.01, 0.44), 0.057 |
| FAI                      | Baseline 8.82 (0.98)         | 9.28 (1.07)                | −0.46 (−1.09, 0.16), 0.143** |
|                          | End 7.87 (0.48)              | 8.83 (0.94)                | −0.67 (−1.5, 0.19), 0.121*** |
|                          | MD (95% CI), P*              | −0.95 (−1.25, −0.66), < 0.001 | −0.45 (−0.58, −0.32), < 0.001 |

DHEAS Dehydroepiandrosterone sulfate, FAI free androgen index, FBG fasting blood glucose, FSH Follicle stimulating hormone, HOMA-IR homeostatic model assessment for insulin resistance, LH Luteinizing hormone, NEFA non-esterified fatty acids (or free fatty acids), QUICKI quantitative insulin sensitivity check index, SHBG sex hormone-binding globulin. Mean (SD) and mean difference (95% CI) are presented for data.* P based on Paired samples t-test.** P based on Independent samples t-test.*** P based on ANCOVA adjusted for baseline values and confounding factors (age, baseline BMI, and the changes in weight, calorie intake, and physical activity level during the study).

combination with calorie-restricted diet for 12 weeks in obese women with PCOS resulted in significant reductions in weight, BMI, WC, WHR, and FM compared to placebo. Meanwhile, these anthropometric indices significantly decreased at the end of the study in both thylakoid and placebo groups, which could be due to receiving the calorie-restricted diet; however, between-group differences were significant at the end of the study. These findings are in line with earlier studies [17, 30, 31]. In a 12-week single-blinded RCT, thylakoids were shown to promote body weight loss significantly when compared to controls among overweight or obese
in body weight compared to the placebo group. However, there were no significant differences in WC, FFM, and body fat percentage between the two groups. Our findings showed that coupled with weight loss, a reduction in body fat mass was the most significant change induced by thylakoids compared to controls. Further, changes in FFM were not significant between the two groups. The findings of a study on an animal model of obesity (Female Sprague-Dawley rats fed a high-fat diet) indicated that oral administration of thylakoids resulted in significantly less food intake over the 13-day study and significantly lower body weights (−18%) compared to the controls [17]. A longer (100 days) trial confirmed the anti-obesity effect of thylakoid supplementation, which lowered food consumption, body fat (−33%), and weight (−27%) in female apo E-deficient mice [32].

Several explanations have been suggested for the positive effects of spinach-derived thylakoids on obesity management. For example, it was demonstrated that thylakoid membranes isolated from spinach inhibited the activity of pancreatic lipase/co-lipase up to 80% in vitro [17]. Thus, thylakoids slow down the digestion and absorption of dietary fat; hence, post-prandial high-fat content in the small intestinal lumen curbs hunger, stimulates satiety signals, and promotes satiety and suppresses appetite [33]. Elevated gut-derived satiety hormone cholecystokinin (CCK) from duodenal enteroendocrine cells following consumption of a thylakoid containing meal, has been reported by Köhnke et al. in healthy humans [30]. In this regard, numerous human trials have been conducted with favorable results on the satiety inducing effects of spinach thylakoids [16, 18, 31, 34]. Overall, significantly elevated levels of the enteroendocrine-derived satiety hormone glucagon-like peptide-1(GLP-1) (+44%) and the adipose-derived satiety hormone leptin were demonstrated. Further, a significant reduction was reported in the serum levels of ghrelin, a stomach-derived hunger hormone, 2-h after consuming a thylakoid-enriched meal [18]. The promotion of satiety as well as suppression of hunger and appetite by thylakoid has been highlighted by previous studies regarding weight loss and anthropometrics improvement effects of spinach-derived thylakoids [35]. Nevertheless, our findings showed that thylakoid supplementation did not alter the energy and dietary nutrient intake in obese women with PCOS. Also, there were no significant differences in energy and dietary intakes between the two groups. Our findings were consistent with the outcomes provided by previous studies [18, 31], which indicated no significant changes in total calorie and nutrient intakes of thylakoid consumers in trials; and the food intake at the next meal following thylakoid intake was not different either between placebo and thylakoid groups. Thus, the exact mechanism of thylakoid affecting anthropometric indices is still unknown. Based on the results of the present clinical trial, 5 g/day of spinach-derived thylakoid supplementation for 12 weeks among obese women with PCOS resulted in significant reductions in insulin levels, HOMA-IR, and HOMA-B. It also significantly elevated QUICKI when compared to the placebo. QUICKI has been suggested as the most extensively validated and accurate surrogate index of insulin sensitivity, so the elevation of this index is indicative of an increase in insulin sensitivity [36]. However, the changes observed in serum levels of FBG and NEFA did not differ significantly between the two groups. Our findings concurred with the findings of Köhnke et al. [30]. They reported that insulin levels were reduced by about 37% in the thylakoid group compared to the control, but blood glucose level changes were not different between the two groups. Significant reductions in insulin levels in thylakoid consumers compared to controls, without considerable differences in glucose level variations between the two groups, suggested increased insulin sensitivity due to thylakoid supplementation. Given the body weight and fat mass reducing effects of thylakoid supplementation in our study, it is expected that thylakoid intake could improve insulin sensitivity and alleviate insulin resistance, as has been demonstrated in other studies [18, 31]. Furthermore, a number of animal studies reported decreased blood glucose levels and improved glucose homeostasis during treatment with thylakoid [24, 32, 37, 38]. These positive effects of spinach-derived thylakoids on glucose homeostasis parameters may be explained by various mechanisms, such as delaying gastric emptying, increasing CCK and GLP-1 secretions, and reducing intestinal uptake of glucose through localization of thylakoids as large complex structures onto the mucosa as well as by binding to the starch and/or amylase, which was observed in rat intestine [24, 37]. Further, the loss of both body weight and fat mass due to thylakoid supplementation could be involved in these beneficial metabolic effects. A loss of body weight is often associated with an increase in the levels of free fatty acids (FFAs). FFAs reduce insulin sensitivity in muscles by inhibiting insulin-mediated glucose uptake. An overflow of circulating FFAs, released from an expanded adipose tissue mass, is the main contributor to the progression of insulin resistance [39]. Several studies have shown a reduction in serum FFAs levels following spinach thylakoid supplementation [30, 32]. Our results show that despite the significant weight loss, FFAs levels did not increase in either groups, and at the end of the study, the differences in FFAs level changes were not significant between the groups. Similar results were observed in some human studies, reporting no
effect of thylakoid supplementation on serum FFAs levels [18, 31]. It seems that a greater improvement in insulin resistance and thus improvement of fatty acid and glucose metabolism might have masked the potentially altered levels of FFAs due to loss of weight and fat mass in our participants. Further, differences in the dosage used or duration of supplementation might have played a role in the studies inconsistent outcomes. We found that 5 g/day of thylakoid-rich spinach extract administration in combination with calorie-restricted diet for 12 weeks among obese women with PCOS led to insignificant changes in the hormonal parameters except for total testosterone level which decreased significantly in the thylakoid group, based on between-group analysis adjusted for baseline values and confounders. To the best of our knowledge, no reports are available indicating the effects of spinach thylakoid supplementation on hormonal status in women with PCOS. Regarding the use of oral contraceptives by all participants to help regulate their irregular menstrual cycle, it is expected that the hormonal profile of these subjects would not change significantly due to thylakoid supplementation. The main outcome of the current study is that spinach thylakoid combined with the calorie-restrictive diet was more effective in reducing testosterone levels than did a calorie-restrictive diet alone. The possible explanations for this effect can be found in the greater reductions of weight and fat mass, as well as greater improvement of insulin resistance in thylakoid consumers on the calorie-restrictive diet, compared to the placebo group. Previous studies have established that calorie restriction and weight loss can reduce insulin levels and improve insulin sensitivity through enhancing adenosine monophosphate-activated protein kinase (AMPK) signaling and affecting the release of inflammatory mediators from visceral adipose tissue [40, 41]. In our study, all participants were obese and insulin-resistant, and both groups received a calorie-restrictive diet. Nevertheless, we found that the reductions in weight, fat mass, and WC in the thylakoid receiving group were significantly lower compared to the placebo receiving group. Thus, because of the interrelated interactions between IR, hyperandrogenism, and obesity, a possible reason for beneficial changes in insulin resistance and serum levels of insulin and testosterone might in part be attributed to the improvement of anthropometric parameters, following spinach thylakoid supplementation in our patients.

The major strength of our trial, as the first clinical trial, was monitoring the patients’ diets by designing calorie-restricted dietary plans with a focus on the amount and type of the macronutrients, and individual preferences, which enhanced compliance. Further, physical activities and dietary intakes were checked before, during, and after the intervention. Furthermore, frequent visits and phone calls increased the participants’ motivation and cooperation. The design of our study, double-blind and the adjustment of measured biochemical parameters for the known confounding factors were the principal strengths of this study. However, the present trial had some limitations including small sample size, the absence of a follow-up evaluation of ovarian masses via sonographic assessment, and not testing for a dose-response relationship between thylakoid intake and appeared changes in the measured parameters. The use of the bioelectrical impedance analysis to assess body composition was the other limitation of this trial. Impedance instruments measure the body’s electrical impedance, and the measured impedance is then used to predict body composition. Thus, body composition is indirectly predicted from impedance due to the involvement of assumptions and estimations in this process. Further, BIA measures are dependent on several factors, such as age, gender, ethnicity, the presence of medical conditions, and hydration status. Hydration or dehydration, exercise, menstruation, consuming alcohol or caffeine, and having a full bladder can all affect the precision of BIA measurements [42].

**Conclusions**

The present study, for the first time, reported that supplementation with 5 g/day spinach-derived thylakoid in combination with a calorie-restrictive diet for 12 weeks may improve anthropometric indices, insulin sensitivity, and testosterone levels in obese women with PCOS. These findings highlighted the fundamental importance of weight loss and lowering BMI in the management of metabolic disturbance in obese women with PCOS. Collectively, these data suggest that spinach-derived thylakoid along with calorie-restrictive diet may be a promising adjunct therapy without any side effects for the management of obesity and insulin sensitivity, in OCP treated obese women with PCOS. Yet, further studies are required to identify the exact mechanisms of these beneficial effects and to confirm the positive effects of spinach-derived thylakoids in obese women with PCOS.

**Abbreviations**

BMI: Body mass index; BIA: Bioelectrical impedance analysis; CCK: Cholecystokinin; CI: Confidence interval; CVs: Coefficient of variances; DHEAS: Dehydroepiandrosterone sulfate; FAI: Free androgen index; FBG: Fasting blood glucose; FFM: Fat free mass; FM: Fat mass; FBS: Fasting blood glucose; FSH: Follicle-stimulating hormone; GLP-1: glucagon-like peptide-1; HOMA-IR: Homeostasis model assessment of insulin resistance; IR: Insulin resistance; LDL-C: Low-density lipoprotein cholesterol; LH: Luteinizing hormone; MUF: Monounsaturated fatty acid; NEFA: Nonesterified fatty acids; OCP: Oral contraceptive pill; PCOS: Polycystic ovary syndrome; PUFA: Polyunsaturated fatty acid; QUICKI: Quantitative insulin sensitivity check index; RCT: Randomized clinical trial; REE: Resting energy expenditure; SD: Standard deviation; SFA: Saturated fatty acid; SHBG: Sex hormone-binding globulin; WC: Waist circumference; WHR: Waist-to-hip ratio
Acknowledgements
We sincerely thank all PCOS women who participated in this clinical trial. The study was a part of Fatemeh Pourteymour Fard Tabrizi’s Ph.D. thesis that was financially supported by a grant from Vice-Chancellor for Research, Tabriz University of Medical Sciences, Tabriz, Iran under the registration code of 59918. We would also like to thank the Iran National Science Foundation (INSF) for its financial support (Grant number #96013888).

Authors’ contributions
FPFT: Contributed to the study conception and design, and data collection and analysis, and drafting of the manuscript. MA: Participated in study design and contributed to the interpretation of data, revising the paper critically, and giving final approval. MV: Contributed to sampling and enrollment of patients and data gathering from study participants, and also contributed to completing this clinical trial. SH: Contributed to preparing of thylakoid supplement from spinach leaves and collecting of data. The authors read and approved the final manuscript.

Funding
The study was financially supported by the grant of Vice-Chancellor for Research, Tabriz University of Medical Sciences, Tabriz, Iran under the registration code of 59918 and the grant of Iran National Science Foundation (INSF) for its financial support (Grant number #96013888).

Availability of data and materials
Data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate
The protocol was approved by the ethics committee of research vice-chancellor of Tabriz University of Medical Sciences, Tabriz, Iran (Ethics code: IR.TBZMED.REC.1:397.A47). After being given a full explanation of the study procedures, written informed consent was obtained from all patients.

Consent for publication
Prior to data collection, the purpose of the study was explained to all participants. After being given a full explanation of the study procedures, written informed consent was obtained from all patients.

Competing interests
All authors declared that they have no potential conflict of interest.

Author details
1 Nutrition Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 2 Drug Applied Research Center, Tabriz University of Medical Sciences, Attar-nejabab Aye, Golgahst St, Tabriz 5166665931, Iran. 3 Department of Obstetrics and Gynecology, Alzahra Teaching Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. 4 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Received: 21 February 2020 Accepted: 6 August 2020
Published online: 11 August 2020

References
1. Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil Steril. 2012;97:28–38.
2. Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Bai G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017;8:9635–1–8.
3. Jalilian A, Kiani F, Sayehmiri F, Sayehmiri K, Khodaei Z, Akbari M. Prevalence of polycystic ovary syndrome and its associated complications in Iranian women: a meta-analysis. Int J Reprod Biomed. 2015;13:591–604.
4. Daniliadis A, Dinas K. Long term health consequences of polycystic ovarian syndrome: a review analysis. Hippokratia. 2009:1390–2.
5. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–92.
6. Cattau-Jonard S, Dewailly D. Pathophysiology of polycystic ovary syndrome: the role of hyperandrogenism. Front Horm Res. 2013;40:22–7.
7. Delgate CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83:1454–60.
8. Lim SS, Davies MJ, Norman RJ, Moran L. J. Obesity, and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18:618–37.
9. Bednarska S, Siejka A. The pathogenesis and treatment of polycystic ovary syndrome: What’s new? Adv Clin Exp Med. 2017;26:359–67.
10. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110:364–79.
11. Panidis D, Farmakiotis D, Roussos D, Koutsis A, Katsikis I, Krasas G. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and/orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril. 2008;89:899–906.
12. Davoodi SH, Ajami M, Ayatollahi SA, Dowlatshahi K, Javedan G, Pazerik-Toroudi HR. Calorie shifting diet versus calorie restriction diet: a comparative clinical trial study. Int J Prev Med. 2014;5:447–56.
13. Costello MF, Misso ML, Wong J, Hart R, Rombauts L, Melder A, et al. The treatment of infertility in polycystic ovary syndrome: a brief update. Aust New Zeal J Obstet Gynaecol. 2012;52:400–3.
14. Papavassiliou K, Papakonstantinou E. Nutritional support and dietary interventions for women with polycystic ovary syndrome. Nutr Diet Suppl. 2017;9:63–85.
15. Arentz S, Smith CA, Abbott J, Bensoussan A. Nutritional supplements and herbal medicines for women with polycystic ovary syndrome: a systematic review and meta-analysis. BMC Complement Altern Med. 2017;17:500.
16. Stenblom E-L, Egecioglu E, Landin-Olsson M, Erlandsson-Albertsson C. Consumption of thylakoid-rich spinach extract reduces hunger, increases satiety and reduces cravings for palatable food in overweight women. Appetite. 2015;91:209–19.
17. Albertsson PÅ, Köhnke R, Emek SC, Mei J, Rehfeld JF, Åkerlund HE, et al. Chloplast membranes retard fat digestion and induce satiety: effect of biological membranes on pancreatic lipase/co-lipase. Biochem J. 2007;401:727–33.
18. Montelius C, Erlandsson D, Vitja E, Stenblom E-L, Egecioglu E, Erlandsson-Albertsson C. Body weight loss, reduced urge for palatable food and increased release of GLP-1 through daily supplementation with green-plant membranes for three months in overweight women. Appetite. 2014;81:295–304.
19. Erlandsson-Albertsson C, Albertsson PÅ. The use of green leaf membranes to promote appetite control, suppress hedonic hunger and loose body weight. Plant Foods Hum Nutr. 2015;70:281–90.
20. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
21. Stenblom E-L, Montelius C, Erlandsson D, Skarping L, Fransson M, et al. Decreased urge for palatable food after a two-month dietary intervention with green-plant membranes in overweight women. J Obes Weight Loss Ther. 2014;041:1–8.
22. Frankenfield DC, Rowe WA, Smith JS, Cooney RN. Validation of several established equations for restoring metabolic rate in obese and nonobese people. J Am Diet Assoc. 2003;103:1152–9.
23. Wheeler ML, Dunbar SA, Jaacks LM, Karmally W, Mayer-Davis EJ, Wylie-Rosett J, et al. Macronutrients, food groups, and eating patterns in the Management of Diabetes. Diabetes Care. 2011;35:434–45.
24. Montelius C, Gustafsson K, Westrom B, Albertsson PÅ, Emek SC, Rayner M, et al. Chloplast thylakoids reduce glucose uptake and decrease intestinal macromolecular permeability. Br J Nutr. 2011;106:386–44.
25. Emek SC, Szilagyi A, Åkerlund HE, Albertsson PÅ, Köhnke R, Holm A, et al. A large scale method for preparation of plant thylakoids for use in body weight regulation. Prep Biochem Biotechnol. 2010;40:15–27.
26. Leszczak J, Czenczek-Lewandowska E, Przysada G, Wyszyńska J, Weres A, Baran J, et al. Diet after stroke and its impact on the components of body mass and functional fitness—a 4-month observation. Nutrients. 2019;11:1227.
27. Pispasret V, Ingram KH, Lopez-Davila MF, Munoz AJ, Garvey WT. Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived
from oral glucose tolerance test in African Americans. Diabetes Care. 2013; 36:845–53.

28. Azziz R, Carmina E, Dewaull D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009; 91:e56–88.

29. Poureyroum Fard Tabrizi F, Abbasalizad Farhangi M. A Systematic Review of the Potential Effects of Thylakoids in the Management of Obesity and Its Related Issues. Food Rev Int. 2020; in Press.

30. Köhnke R, Lindbo A, Larsson T, Lindqvist A, Rayner M, Emek SC, et al. Thylakoids promote release of the satiety hormone cholecystokinin while reducing insulin in healthy humans. Scand J Gastroenterol. 2009;44:712–9.

31. Rebello CJ, Chu J, Belyl R, Edwall D, Erlanson-Albertsson C, Greenway FL. Acute effects of a spinach extract rich in thylakoids on satiety: a randomized controlled crossover trial. J Am Coll Nutr. 2015;34:470–7.

32. Köhnke R, Lindqvist A, Göransson N, Emek SC, Albertsson PA, Rehfeld JF, Hultgårdh-Nilsson AE-AC. Thylakoids suppress appetite by increasing cholecystokinin resulting in lower food intake and body weight in high-fat fed mice. Phyther Res. 2009;23:1778–83.

33. Maljaars J, Peters HPF, Masclee AM. The gastrointestinal tract: neuroendocrine regulation of satiety and food intake. Aliment Pharmacol Ther. 2007;26:241–50.

34. Sterblom EL, Montelius C, Östbring K, Håkansson N, Nilsson S, Rehfeld JF, et al. Supplementation by thylakoids to a high carbohydrate meal decreases feelings of hunger, elevates CCK levels and prevents postprandial hypoglycaemia in overweight women. Appetite. 2013;68:118–23.

35. Panda V, Shinde P. Appetite suppressing effect of Spinacia oleracea in rats: involvement of the short term satiety signal cholecystokinin. Appetite. 2017;113:224–30.

36. Katz A, Nambi SS, Mather K, Baron AD, Fallmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85: 2402–10.

37. Montelius C, Osman N, Weström B, Ahmé S, Molin G, Albertsson PÅ, et al. Feeding spinach thylakoids to rats modulates the gut microbiota, decreases food intake and affects the insulin response. J Nutr Sci. 2013;2:1–9.

38. Montelius C, Szwiec K, Kardas M, Lozinska L, Erlanson-Albertsson C, Pierzynowski S, et al. Dietary thylakoids suppress blood glucose and modulate appetite-regulating hormones in pigs exposed to oral glucose tolerance test. Clin Nutr. 2014;33:1122–6.

39. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes. 2011;60:2441–9.

40. Mamanti M, Kulkarni H, Dyer TD, Almassy L, Mahaney MC, Duggirala R, et al. Waist circumference independently associates with the risk of insulin resistance and type 2 diabetes in Mexican American families. PLoS One. 2013;8:e59153.

41. Ye J. Mechanisms of insulin resistance in obesity. Front Med China. 2013;7:14–24.

42. Böhm A, Heitmann BL. The use of bioelectrical impedance analysis for body composition in epidemiological studies. Eur J Clin Nutr. 2013;67:579–85.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.